Tag: Innovative Medicines

PhagoMed Biopharma receives ‘Phönix 2018’ award in Austria

scientist
Vienna-based Biotech company PhagoMed Biopharma was awarded the Austrian Entrepreneurship Award 'Phönix 2018' in the category “Start-Up International”.

Sandoz and Pear Therapeutics launched the first digital therapeutic

digital drug
Sandoz, a Novartis division, and Pear Therapeutics, announced the commercial launch of reSET, the first FDA-authorized prescription digital therapeutic, for patients with Substance Use Disorder.

Russian scientists started trials for new ankylosing spondylitis drug

research
Scientists of the N.I. Pirogov Russian National Research Medical University began trials of the world's first drug without any side effects for the treatment of an incurable joint disease.

Nacimbio and Lomonosov MSU to develop new immunobiological preparations

research
Pharmaceutical Holding State Corporation Rostec 'Nacimbio' and M.V. Lomonosov Moscow State University agreed on long-term cooperation in the development of innovative immunobiological drugs.

Sechenov University welcomes the European Congress on eCardiology and eHealth

cardiology
On October 29-30, 2018 Sechenov University will hold the 5th European Congress on eCardiology and eHealth: "Connecting clinicians and technology to implement eHealth in daily practice".

Otsuka extended collaboration on digital medicines with Proteus Digital Health

digital-drug
Otsuka Pharmaceutical and Proteus Digital Health announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies.

MEI Pharma and BeiGene will jointly develop cancer drugs

laboratory test
MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401 in combination with BeiGene's zanubrutinib.

Researchers unveiled the first bio-electronic medicine

digital drug
Researchers at Northwestern University and Washington University School of Medicine have developed the first example of a bioresorbable electronic medicine.

Manturov: By launching innovative drugs, we will ensure a fold increase in exports

drug
The export of Russian pharmaceutical products in the coming years will increase several-fold and in five years will reach $ 3-4 billion a year through the launch of innovative drugs,

Sinopharm and Oramed received $600 million for their oral insulin candidate

oral-insulin
Harbin Gloria Pharmaceuticals took a $600 million stake in a subsidiary of SINOPHARM GROUP whose lead product is an oral insulin candidate being codeveloped with Israeli biotech Oramed Pharmaceuticals.

GSK and 23andMe entered an exclusive R&D collaboration

gsk
GSK and 23andMe unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery.

Anima Biotech signs a drug discovery agreement with Lilly

drug-development
Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform.

PureTech Health entered into a multiyear collaboration with Roche

microscope
PureTech Health, a clinical-stage biopharmaceutical company developing novel medicines focused on the Brain-Immune-Gut (BIG) Axis, announced that it has entered into a multiyear collaboration with Roche.

South Korean company acquires AMPAC Fine Chemicals

api
SK Holdings, the parent company of South Korea’s third-largest conglomerate SK Group, announced that it has acquired a 100 percent stake in AMPAC Fine Chemicals, a US-based contract manufacturer of APIs.

Harvard researchers developed a new method to deliver insulin orally

lab-tubes
Scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences have developed an oral delivery method that could dramatically transform the way in which diabetics keep their blood sugar levels in check.

Juvenescence receives $50 million to develop anti-aging therapies

antii-aging
Juvenescence Limited, a leader in the development of therapies to slow, halt or potentially reverse aging, has successfully raised $50 million in its Series A financing.